| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 技术授权许可(元) | 8,565,340.00 | 2,199,477.41 | 1,090,364.80 | 2,356,368.70 | 2,900,445.70 |
| 销售商品(元) | 526,644,686.69 | - | 397,647,375.90 | - | 292,529,501.33 |
| 西达本胺片销售(元) | - | 579,740,128.28 | - | 499,541,051.62 | - |
| 西格列他钠销售收入(元) | - | 311,935,482.98 | - | 140,159,890.19 | - |
| 其他(元) | 51,507.84 | 1,956,485.18 | 517,120.84 | 2,444,251.40 | 6,730,562.02 |
| 营业成本(元) | |||||
| 技术授权许可(元) | 1,766,666.67 | - | - | - | - |
| 销售商品(元) | 68,589,903.78 | - | 49,439,730.14 | - | 33,253,547.67 |
| 西达本胺片销售(元) | - | 37,404,866.05 | - | 33,611,091.03 | - |
| 西格列他钠销售收入(元) | - | 71,022,583.40 | - | 46,666,054.89 | - |
| 其他(元) | 713,391.87 | 2,430,154.22 | 1,169,982.69 | 1,818,446.55 | 3,262,796.80 |
| 毛利(元) | |||||
| 技术授权许可(元) | 6,798,673.33 | 2,199,477.41 | 1,090,364.80 | 2,356,368.70 | 2,900,445.70 |
| 销售商品(元) | 458,054,782.91 | - | 348,207,645.76 | - | 259,275,953.66 |
| 西达本胺片销售(元) | - | 542,335,262.23 | - | 465,929,960.59 | - |
| 西格列他钠销售收入(元) | - | 240,912,899.58 | - | 93,493,835.30 | - |
| 其他(元) | -661,884.03 | -473,669.04 | -652,861.85 | 625,804.85 | 3,467,765.22 |
| 毛利率(%) | |||||
| 技术授权许可(%) | 79.37 | - | - | - | - |
| 销售商品(%) | 86.98 | - | 87.57 | - | 88.63 |
| 西达本胺片销售(%) | - | 93.55 | - | 93.27 | - |
| 西格列他钠销售收入(%) | - | 77.23 | - | 66.71 | - |
| 其他(%) | -1,285.02 | -24.21 | -126.25 | 25.60 | 51.52 |
| 收入构成(%) | |||||
| 技术授权许可(%) | 1.60 | 0.25 | 0.27 | 0.37 | 0.96 |
| 销售商品(%) | 98.39 | - | 99.60 | - | 96.81 |
| 西达本胺片销售(%) | - | 64.72 | - | 77.51 | - |
| 西格列他钠销售收入(%) | - | 34.82 | - | 21.75 | - |
| 其他(%) | 0.01 | 0.22 | 0.13 | 0.38 | 2.23 |
| 毛利构成(%) | |||||
| 技术授权许可(%) | 1.46 | 0.28 | 0.31 | 0.42 | 1.09 |
| 销售商品(%) | 98.68 | - | 99.87 | - | 97.60 |
| 西达本胺片销售(%) | - | 69.09 | - | 82.85 | - |
| 西格列他钠销售收入(%) | - | 30.69 | - | 16.62 | - |
| 其他(%) | -0.14 | -0.06 | -0.19 | 0.11 | 1.31 |